Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11570717 | 0.91 | VCAM1 (0.35) | VCAM1CA2 | |
| SCHEMBL7046706 | 0.89 | VCAM1 (0.36) | VCAM1PIK3CDCA2PER2CRY1 | |
| SCHEMBL11575979 | 0.79 | MAPK1 (0.40) | MAPK1TSHR | |
| SCHEMBL3049834 | 0.78 | PIK3CD (0.37) | VCAM1PIK3CDCA2 | |
| SCHEMBL16451224 | 0.77 | PER2 (0.42) | VCAM1PIK3CDCA2PER2CRY1 | |
| SCHEMBL25257892 | 0.75 | VCAM1 (0.35) | VCAM1PIK3CDPER2CRY1CRY2 | |
| SCHEMBL21413190 | 0.75 | MAPK1 (0.35) | VCAM1PIK3CDPER2CRY1CRY2 | |
| SCHEMBL30615262 | 0.73 | CA1 (0.30) | — | |
| SCHEMBL3921692 | 0.71 | VCAM1 (0.33) | VCAM1PIK3CDPER2CRY1CRY2 | |
| SCHEMBL24662660 | 0.71 | PER2 (0.39) | VCAM1PIK3CDPER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368075-A1 | Synthesis of N,N-Dialkyl, -Dialkenyl, -Dialkynyl, and Related Cyclics, Sulfamoyl Fluoride Compounds Using Hydrogen Fluoride | SES HOLDINGS PTE. LTD. (SG) | 2024-11-07 | — | — | US | disclosed |
| EP-4363400-A1 | SYNTHESIS OF N,N-DIALKYL, -DIALKENYL, -DIALKYNYL, AND RELATED CYCLICS, SULFAMOYL FLUORIDE COMPOUNDS USING HYDROGEN FLUORIDE | SES Holdings Pte. Ltd. (SG) | 2024-05-08 | — | — | EP | disclosed |
| CN-117500784-A | Synthesis of N, N-dialkylsulfamoyl fluoride compounds, N-dienylsulfamoyl fluoride compounds, N-dialkynyl sulfamoyl fluoride compounds and related cyclic sulfamoyl fluoride compounds using hydrogen fluoride | 麻省固能控股有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023275607-A1 | SYNTHESIS OF N,N-DIALKYL, -DIALKENYL, -DIALKYNL, AND RELATED CYCLICS, SULFAMOYL FLUORIDE COMPOUNDS USING HYDROGEN FLUORIDE | SES HOLDINGS PTE. LTD. (SG) | 2023-01-05 | — | — | WO | disclosed |
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | NEKTAR THERAPEUTICS (US) | 2022-02-08 | — | — | US | disclosed |
| US-10934280-B2 | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | ELI LILLY AND COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| CN-109563070-B | Fused thiophene derivatives as NAPI-IIB inhibitors | 伊莱利利公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3497091-B1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | LILLY CO ELI (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200031813-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | ELI LILLY AND COMPANY | 2020-01-30 | — | — | US | disclosed |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2019-09-05 | — | — | US | disclosed |
| EP-3237388-B1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3497091-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | Eli Lilly and Company (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | NEKTAR THERAPEUTICS (US) | 2019-06-18 | — | — | US | disclosed |
| WO-2018034883-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20170368029-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2017-12-28 | — | — | US | disclosed |
| EP-3237388-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | Nektar Therapeutics (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106133-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2016-06-30 | — | — | WO | disclosed |
| US-6458783-B1 | INHIBITION OF FARNESYL TRANSFERASE, WHICH IS AN ENZYME INVOLVED IN RAS ONCOGENE EXPRESSION, IS EFFECTED BY COMPOUNDS OF THE FORMULAS OF BENODIAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-01 | — | — | US | disclosed |
| WO-2001081322-A1 | NON-IMIDAZOLE BENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368029-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | OPRK1, OPRM1, OPRD1 | VCAM1 2756/4885PIK3CD 3568/4885CA2 1598/4885 |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | OPRK1, OPRM1, OPRD1 | VCAM1 2756/4885PIK3CD 3568/4885CA2 1598/4885 |
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | OPRM1, OPRK1, OPRD1 | VCAM1 2917/4885PIK3CD 3833/4885CA2 1594/4885 |
| US-10934280-B2 | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | SLC34A2, ALPI, SLC34A1 | VCAM1 1578/4885PIK3CD 296/4885CA2 95/4885 |
| US-20200031813-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | SLC34A2, ALPI, SLC34A1 | VCAM1 1578/4885PIK3CD 296/4885CA2 95/4885 |
| US-20240368075-A1 | Synthesis of N,N-Dialkyl, -Dialkenyl, -Dialkynyl, and Related Cyclics, Sulfamoyl Fluoride Compounds Using Hydrogen Fluoride | NR2C2, NOC2L, NR2E1 | VCAM1 4594/4885PIK3CD 2265/4885CA2 1123/4885 |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | OPRK1, OPRM1, OPRD1 | VCAM1 2756/4885PIK3CD 3568/4885CA2 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.